Table 1.
Patient demographics of the study cohort prior to immunotherapy initiation (n = 70).
| Demographic Variables | Number of Patients (%) |
|---|---|
| Age (years) | |
| Median | 71 |
| Range | 29–91 |
| Gender | |
| Male | 49 (70) |
| Female | 21 (30) |
| ECOG | |
| 0 | 53 (75) |
| 1 | 11 (16) |
| ≥2 | 6 (9) |
| Stage at commencement of anti-PD1 | |
| M1a | 20 (29) |
| M1b | 12 (17) |
| M1c | 31 (44) |
| M1d | 7 (10) |
| Number of metastatic sites | |
| <3 | 54 (77) |
| >3 | 16 (23) |
| Lines of prior therapy | |
| 0 | 36 (51) |
| ≥1 | 34 (49) |
| Prior systemic therapy | |
| Chemotherapy (DTIC/Fotemustine) | 5 (7) |
| BRAFi or BRAF/MEKi | 13 (19) |
| Ipilimumab | 15 (21) |
| BRAF V600 mutation | |
| Yes | 14 (20) |
| No | 56 (80) |
| LDH prior to anti-PD1 therapy | |
| <ULN | 49 (70) |
| >1×ULN | 13 (19) |
| >2×ULN | 3 (4) |
| Unknown | 5 (7) |
| Brain metastases | |
| Absent | 63 (90) |
| Present | 7 (10) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; AJCC, American Joint Committee on Cancer (8th edition); DTIC, Dacarbazine; LDH, lactate dehydrogenase; ULN, upper limit of normal.